/

Society

IN

Not verified

INVENTIVA

What we write about

Foreign PolicyPharmaceuticals

18 Press releases

View all press releases

25/09/2024

Pharmaceuticals

Foreign Policy

Inventiva fait un point sur ses activités et publie ses résultats financiers non audités du premier semestre 2024

Source

Issuer

1.00

0

25/09/2024

Pharmaceuticals

Foreign Policy

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Source

Issuer

1.00

0

31/07/2024

Pharmaceuticals

Foreign Policy

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Source

Issuer

1.00

0

31/07/2024

Pharmaceuticals

Foreign Policy

Inventiva publie ses informations financières préliminaires du premier semestre 2024¹

Source

Issuer

1.00

0

25/07/2024

Pharmaceuticals

Foreign Policy

Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor

Source

Issuer

1.00

0

25/07/2024

Pharmaceuticals

Foreign Policy

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Source

Issuer

1.00

0

17/07/2024

Pharmaceuticals

Foreign Policy

Inventiva announces a €20.1 million issuance of royalty certificates

Source

Issuer

1.00

0

17/07/2024

Pharmaceuticals

Foreign Policy

Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros

Source

Issuer

1.00

0

05/07/2024

Pharmaceuticals

Foreign Policy

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Source

Issuer

1.00

0

05/07/2024

Pharmaceuticals

Foreign Policy

Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièr

Source

Issuer

1.00

0

Followers

0

Compatibility

0